J&J Wins FDA Nod for Dual-Energy Ablation Platform
Event summary
- Johnson & Johnson received FDA approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform (DE STSF) on July 8, 2026.
- The platform integrates both radiofrequency (RF) and pulsed field (PF) energy delivery in a single catheter.
- First U.S. procedures with DE STSF are expected to begin this summer following a phased commercial rollout.
- The technology builds on the existing THERMOCOOL SMARTTOUCH SF Platform, which has treated over one million patients in the U.S.
The big picture
This approval extends J&J's leadership in cardiac ablation technology, addressing unmet needs in treating atrial fibrillation and other rhythm disorders. The dual-energy capability positions the company to capture procedural flexibility as electrophysiology evolves toward more anatomically diverse patient cases. With over one million prior procedures using its platform, J&J leverages established physician trust while expanding into higher-complexity interventions.
What we're watching
- Adoption Pace
- How quickly electrophysiologists will integrate dual-energy capabilities into complex procedures.
- Market Differentiation
- Whether J&J can sustain competitive advantage against rivals developing similar multi-energy platforms.
- Revenue Impact
- The contribution margin from DE STSF adoption relative to existing ablation technologies.
Related topics